Device Debut: Oncimmune Pushes Liver Cancer Test In The US
Executive Summary
Oncimmune has expanded its offering in the US with the launch of a blood-based liver cancer test, the second product to emerge from its EarlyCDT platform.
You may also be interested in...
Oncimmune Kicks Off 2018 With China Pact For Lung Cancer Test
Oncimmune's commercialization of its early cancer diagnostic technology continues to gather pace as the firm enlists yet another distribution partner in Asia. The exclusive deal is for China, where the market opportunity for the company's EarlyCDT-Lung test is sizeable. The agreement also includes an equity investment by the Chinese partner in Oncimmune.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.